PBYI - プ―マ・バイオテクノロジ― (Puma Biotechnology Inc)

PBYIのニュース

   Celcuity Announces Breast Cancer Clinical Trial Collaboration with MD Anderson, Novartis, and Puma Biotechnology to Study New Drug Regimen  2021/03/16 20:00:00 Business Wire
Celcuity Announces Breast Cancer Clinical Trial Collaboration with MD Anderson, Novartis, and Puma Biotechnology to Study New Drug Regimen
   Puma Biotechnology to Present at the Barclays Global Healthcare Conference  2021/03/04 21:15:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach, CEO & President, will present an overview of Puma Biotechnology at the virtual Barclays Global Healthcare Conference on March 11, 2021.
   Puma Biotechnology to Present at the H.C. Wainwright Global Life Sciences Conference  2021/03/02 21:20:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach will present an overview of Puma Biotechnology at H.C. Wainwright's Global Health Care Conf, available online beginning March 9, 2021.
   Samenvatting: Puma Biotechnology en Pierre Fabre passen de NERLYNX®-licentieovereenkomst aan om ook Groot-China op te nemen  2021/02/26 19:47:00 Business Wire
LOS ANGELES & CASTRES, Frankrijk--(BUSINESS WIRE)--Puma Biotechnology, Inc. (Nasdaq: PBYI), een biofarmaceutisch bedrijf, en Pierre Fabre, een toonaangevend Frans farmaceutisch bedrijf, zijn overeengekomen de voorwaarden van de licentieovereenkomst van 2019 te verlengen. Pierre Fabre exclusieve rechten om NERLYNX® (neratinib) te ontwikkelen en te commercialiseren binnen Europa, Turkije, het Midden-Oosten en Afrika. De gewijzigde overeenkomst breidt de commerciële rechten van Pierre Fabre voor N
   The Daily Biotech Pulse: Adcom Test Awaits J&J's COVID-19 Vaccine, Lilly To Supply Additional Antibody Therapy Doses To US, Regulatory Setback For Tricida  2021/02/26 13:16:52 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 25) Apyx Medical Corp (NASDAQ: APYX ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) (announced an $18-million private placement) Bioatla Inc (NASDAQ: BCAB ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Glaukos Corp (NYSE: GKOS ) Myriad Genetics, Inc. (NASDAQ: MYGN ) Organogenesis Holdings Inc (NASDAQ: ORGO ) Pacira Biosciences Inc (NASDAQ: PCRX ) (announced fourth-quarter results) Pandion Therapeutics Inc (NASDAQ: PAND ) - announced a deal to be bought by Merck & Co., Inc. (NYSE: MRK ) for $1.85 billion Pliant Therapeutics Inc (NASDAQ: PLRX ) Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Feb. 25) Acutus Medical Inc (NASDAQ: AFIB ) Aptose Biosciences Inc (NASDAQ: APTO ) Bioventus Class A Ord Shs (Proposed) (NASDAQ: BVS ) Epizyme Inc (NASDAQ: EPZM ) Intercept Pharmaceuticals Inc (NASDAQ: ICPT ) (reacted to fourth-quarter results) Lucira Health Inc (NASDAQ: LHDX ) Opthea Spon American Depositary Receipts Representing 8 Ord Shs (NASDAQ: OPT ) Sensei Biotherapeutics Inc (NASDAQ: SNSE ) Virios Therapeutics LLC (NASDAQ: VIR ) Voyager Therapeutics Inc (NASDAQ: VYGR ) Stocks In Focus Tricida Receives Appeals Denied Letter From FDA Regarding Veverimer Tricida Inc (NASDAQ: TCDA ) said it has received an appeal denied letter, or ADL, from the FDA's Office of New Drugs in response to a formal dispute resolution request submitted in December regarding its NDA for veverimer, which is being evaluated as a treatment option for metabolic acidosis in chronic kidney disease patients.
   Celcuity Announces Breast Cancer Clinical Trial Collaboration with MD Anderson, Novartis, and Puma Biotechnology to Study New Drug Regimen  2021/03/16 20:00:00 Business Wire
Celcuity Announces Breast Cancer Clinical Trial Collaboration with MD Anderson, Novartis, and Puma Biotechnology to Study New Drug Regimen
   Puma Biotechnology to Present at the Barclays Global Healthcare Conference  2021/03/04 21:15:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach, CEO & President, will present an overview of Puma Biotechnology at the virtual Barclays Global Healthcare Conference on March 11, 2021.
   Puma Biotechnology to Present at the H.C. Wainwright Global Life Sciences Conference  2021/03/02 21:20:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach will present an overview of Puma Biotechnology at H.C. Wainwright's Global Health Care Conf, available online beginning March 9, 2021.
   Samenvatting: Puma Biotechnology en Pierre Fabre passen de NERLYNX®-licentieovereenkomst aan om ook Groot-China op te nemen  2021/02/26 19:47:00 Business Wire
LOS ANGELES & CASTRES, Frankrijk--(BUSINESS WIRE)--Puma Biotechnology, Inc. (Nasdaq: PBYI), een biofarmaceutisch bedrijf, en Pierre Fabre, een toonaangevend Frans farmaceutisch bedrijf, zijn overeengekomen de voorwaarden van de licentieovereenkomst van 2019 te verlengen. Pierre Fabre exclusieve rechten om NERLYNX® (neratinib) te ontwikkelen en te commercialiseren binnen Europa, Turkije, het Midden-Oosten en Afrika. De gewijzigde overeenkomst breidt de commerciële rechten van Pierre Fabre voor N
   The Daily Biotech Pulse: Adcom Test Awaits J&J's COVID-19 Vaccine, Lilly To Supply Additional Antibody Therapy Doses To US, Regulatory Setback For Tricida  2021/02/26 13:16:52 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 25) Apyx Medical Corp (NASDAQ: APYX ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) (announced an $18-million private placement) Bioatla Inc (NASDAQ: BCAB ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Glaukos Corp (NYSE: GKOS ) Myriad Genetics, Inc. (NASDAQ: MYGN ) Organogenesis Holdings Inc (NASDAQ: ORGO ) Pacira Biosciences Inc (NASDAQ: PCRX ) (announced fourth-quarter results) Pandion Therapeutics Inc (NASDAQ: PAND ) - announced a deal to be bought by Merck & Co., Inc. (NYSE: MRK ) for $1.85 billion Pliant Therapeutics Inc (NASDAQ: PLRX ) Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Feb. 25) Acutus Medical Inc (NASDAQ: AFIB ) Aptose Biosciences Inc (NASDAQ: APTO ) Bioventus Class A Ord Shs (Proposed) (NASDAQ: BVS ) Epizyme Inc (NASDAQ: EPZM ) Intercept Pharmaceuticals Inc (NASDAQ: ICPT ) (reacted to fourth-quarter results) Lucira Health Inc (NASDAQ: LHDX ) Opthea Spon American Depositary Receipts Representing 8 Ord Shs (NASDAQ: OPT ) Sensei Biotherapeutics Inc (NASDAQ: SNSE ) Virios Therapeutics LLC (NASDAQ: VIR ) Voyager Therapeutics Inc (NASDAQ: VYGR ) Stocks In Focus Tricida Receives Appeals Denied Letter From FDA Regarding Veverimer Tricida Inc (NASDAQ: TCDA ) said it has received an appeal denied letter, or ADL, from the FDA's Office of New Drugs in response to a formal dispute resolution request submitted in December regarding its NDA for veverimer, which is being evaluated as a treatment option for metabolic acidosis in chronic kidney disease patients.
   Celcuity Announces Breast Cancer Clinical Trial Collaboration with MD Anderson, Novartis, and Puma Biotechnology to Study New Drug Regimen  2021/03/16 20:00:00 Business Wire
Celcuity Announces Breast Cancer Clinical Trial Collaboration with MD Anderson, Novartis, and Puma Biotechnology to Study New Drug Regimen
   Puma Biotechnology to Present at the Barclays Global Healthcare Conference  2021/03/04 21:15:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach, CEO & President, will present an overview of Puma Biotechnology at the virtual Barclays Global Healthcare Conference on March 11, 2021.
   Puma Biotechnology to Present at the H.C. Wainwright Global Life Sciences Conference  2021/03/02 21:20:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach will present an overview of Puma Biotechnology at H.C. Wainwright's Global Health Care Conf, available online beginning March 9, 2021.
   Samenvatting: Puma Biotechnology en Pierre Fabre passen de NERLYNX®-licentieovereenkomst aan om ook Groot-China op te nemen  2021/02/26 19:47:00 Business Wire
LOS ANGELES & CASTRES, Frankrijk--(BUSINESS WIRE)--Puma Biotechnology, Inc. (Nasdaq: PBYI), een biofarmaceutisch bedrijf, en Pierre Fabre, een toonaangevend Frans farmaceutisch bedrijf, zijn overeengekomen de voorwaarden van de licentieovereenkomst van 2019 te verlengen. Pierre Fabre exclusieve rechten om NERLYNX® (neratinib) te ontwikkelen en te commercialiseren binnen Europa, Turkije, het Midden-Oosten en Afrika. De gewijzigde overeenkomst breidt de commerciële rechten van Pierre Fabre voor N
   The Daily Biotech Pulse: Adcom Test Awaits J&J's COVID-19 Vaccine, Lilly To Supply Additional Antibody Therapy Doses To US, Regulatory Setback For Tricida  2021/02/26 13:16:52 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 25) Apyx Medical Corp (NASDAQ: APYX ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) (announced an $18-million private placement) Bioatla Inc (NASDAQ: BCAB ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Glaukos Corp (NYSE: GKOS ) Myriad Genetics, Inc. (NASDAQ: MYGN ) Organogenesis Holdings Inc (NASDAQ: ORGO ) Pacira Biosciences Inc (NASDAQ: PCRX ) (announced fourth-quarter results) Pandion Therapeutics Inc (NASDAQ: PAND ) - announced a deal to be bought by Merck & Co., Inc. (NYSE: MRK ) for $1.85 billion Pliant Therapeutics Inc (NASDAQ: PLRX ) Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Feb. 25) Acutus Medical Inc (NASDAQ: AFIB ) Aptose Biosciences Inc (NASDAQ: APTO ) Bioventus Class A Ord Shs (Proposed) (NASDAQ: BVS ) Epizyme Inc (NASDAQ: EPZM ) Intercept Pharmaceuticals Inc (NASDAQ: ICPT ) (reacted to fourth-quarter results) Lucira Health Inc (NASDAQ: LHDX ) Opthea Spon American Depositary Receipts Representing 8 Ord Shs (NASDAQ: OPT ) Sensei Biotherapeutics Inc (NASDAQ: SNSE ) Virios Therapeutics LLC (NASDAQ: VIR ) Voyager Therapeutics Inc (NASDAQ: VYGR ) Stocks In Focus Tricida Receives Appeals Denied Letter From FDA Regarding Veverimer Tricida Inc (NASDAQ: TCDA ) said it has received an appeal denied letter, or ADL, from the FDA's Office of New Drugs in response to a formal dispute resolution request submitted in December regarding its NDA for veverimer, which is being evaluated as a treatment option for metabolic acidosis in chronic kidney disease patients.

calendar